Compugen Ltd.
HealthcareNASDAQ:CGEN · NASDAQ Global Market
+$0.00 today
Vol 0.21M · Avg 0.48M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$72.7M of revenue converted into $34.9M of net income for the selected period. Gross margin is 22.8% and net margin is -305.3%, showing how much revenue survives after costs and taxes. EPS is $0.37, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M +161.1% | $27.9M -16.7% | $33.5M +346.1% | $7.5M +25.0% | $6.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.3M +16.7% | $7.9M +295.7% | $2.0M +105.5% | $975.0K +43.4% | $680.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $63.5M +218.6% | $19.9M -36.6% | $31.5M +382.1% | $6.5M +22.7% | $5.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 87.3% +15.7pp | 71.5% -22.5pp | 94.0% +7.0pp | 87.0% -1.7pp | 88.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $22.8M -8.3% | $24.8M -28.0% | $34.5M +12.5% | $30.6M +6.8% | $28.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $9.4M -5.8% | $10.0M +0.4% | $10.0M -11.3% | $11.3M -3.8% | $11.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $32.2M -7.6% | $34.8M -21.6% | $44.4M +6.1% | $41.9M +3.7% | $40.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $475.0K -2.3% | $486.0K +2.1% | $476.0K -1.2% | $482.0K +4.6% | $461.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $35.9M +490.4% | -$9.2M +0.9% | -$9.3M +72.0% | -$33.1M +1.7% | -$33.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 49.3% +82.3pp | -33.0% -5.3pp | -27.7% +414.0pp | -441.7% +120.3pp | -562.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $31.3M +310.4% | -$14.9M -14.6% | -$13.0M +63.3% | -$35.4M -0.9% | -$35.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 43.1% +96.5pp | -53.4% -14.6pp | -38.8% +432.8pp | -471.7% +112.9pp | -584.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.4M -15.8% | $5.2M +61.6% | $3.2M +125.5% | $1.4M +60.7% | $894.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $34.0K +9.7% | $31.0K +14.8% | $27.0K +8.0% | $25.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.1M -21.4% | $5.2M +61.5% | $3.2M +84.6% | $1.7M +99.5% | $871.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $35.4M +464.6% | -$9.7M +0.8% | -$9.8M +70.9% | -$33.6M +1.7% | -$34.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 48.6% +83.5pp | -34.8% -5.6pp | -29.2% +419.2pp | -448.5% +121.6pp | -570.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $54.0K -98.8% | $4.5M -49.6% | $9.0M +15365.5% | $58.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $35.3M +348.4% | -$14.2M +24.1% | -$18.8M +44.3% | -$33.7M +1.5% | -$34.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | 48.6% +99.6pp | -51.1% +5.0pp | -56.1% +393.2pp | -449.3% +120.8pp | -570.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +337.5% | -$0 +23.8% | -$0 +46.2% | -$0 +4.9% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +337.5% | -$0 +23.8% | -$0 +46.2% | -$0 +4.9% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $93.4M +4.4% | $89.5M +2.2% | $87.6M +1.2% | $86.6M +2.8% | $84.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $93.8M +4.8% | $89.5M +2.2% | $87.6M +1.2% | $86.6M +2.8% | $84.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Nuvectis Pharma, Inc.
NASDAQ:NVCT
$284.09M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$180.93M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CGEN generate?
Compugen Ltd. (CGEN) reported $72.76M of revenue in fiscal 2025.
Is CGEN profitable?
Compugen Ltd. (CGEN) reported $35.34M of net income, with a net margin of 48.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.